Introduction
============

According to the International Association of the Study of Pain, pain can be defined as a disagreeable sensorial and emotional sensation associated with real or potential tissue damage.[@b1-ceor-4-039] Its duration can be classified as acute or chronic, although it is sometimes difficult to distinguish between the two in clinical practice, because pain often has an oscillating presentation, sometimes with pain-free periods.[@b2-ceor-4-039] Acute pain is of short duration, often has an identifiable cause, and responds well to analgesics. In contrast, chronic pain is often independent of the original cause, is usually more difficult to treat, and can itself be considered as an illness. Chronic pain is a public health problem worldwide.[@b3-ceor-4-039]--[@b5-ceor-4-039] Pain is a multidimensional problem influenced by biological, psychological, and social factors. Chronic pain will become more prevalent in the future, owing to increased life expectancy. Currently, the prevalence of chronic pain ranges from 10.1% to 55.2%, depending on the population studied and the study design, although current evidence suggests that approximately 20% of the adult population (aged over 18 years) in developing countries suffers from chronic pain.[@b6-ceor-4-039]--[@b10-ceor-4-039] Chronic pain can be considered as the third most important health problem in our setting, after cardiovascular disease and cancer, and has important economic repercussions, not only associated with medical, surgical and pharmaceutical costs, but also with work absenteeism, disability, and diminished quality of life.[@b11-ceor-4-039]--[@b13-ceor-4-039]

The World Health Organization analgesic ladder, based on the severity of pain (step 1, mild pain; step 2, moderate pain; and step 3, intense pain), reserves treatment with opiates for moderate-severe pain.[@b14-ceor-4-039]--[@b16-ceor-4-039] This therapeutic approach has been shown to be very effective in treating cancer pain. However, the use of opiates for noncancer pain is controversial, because of concerns about their efficacy and safety, and the possibility of addiction.[@b17-ceor-4-039],[@b18-ceor-4-039] There is some evidence to suggest that chronic pain tends to go undertreated. Important contributing factors include: insufficient information about pain physiology; low sensitivity and specificity of the diagnosis; a lack of treatment guidelines reached by consensus; poor understanding of the medicinal products used, mainly of their mechanisms of action; reluctance to use certain pharmacological agents (especially opiates); and/or concern about the development of side effects, interactions, tolerance, or addiction (safety of the medication).[@b19-ceor-4-039],[@b20-ceor-4-039] In the light of this situation, more controlled clinical trials are required to establish a role for opiate therapy in the treatment of chronic pain and to identify criteria that can be used to select patients and treatment algorithms. This study is considered to be of relevance, owing to the insufficient epidemiological studies in patients with chronic pain and of the associated costs (economic analyses). This article presents the results of a retrospective observational study that compiled systematic sociosanitary, clinical, and health care data related to pain treatment in patients with chronic illnesses in an urban area of Spain. The aim was to determine patterns of analgesic drug therapy in routine clinical practice, the resources used, and the associated costs, with the aim of guiding future studies of cost-effectiveness and determining cost-related factors in the Spanish population with chronic pain.

Materials and methods
=====================

Design and study population
---------------------------

A retrospective multicenter study was carried out by examining the medical records (computer databases) of patients followed in an outpatient setting and in hospital. The study population comprised patients from six primary care centers, ie, Apenins-Montigala, Morera-Pomar, Montgat-Tiana, Nova Lloreda, La Riera, and Marti-Julia, managed by Badalona Serveis Assistencials SA. Information was obtained about the resources available in the two reference hospitals, ie, Hospital Municipal de Badalona and Hospital Germans Trías i Pujol (specialist care). The patients assigned to these centers mainly come from urban areas, have middle-low economic status, and mostly work in industry.

Inclusion and exclusion criteria
--------------------------------

All patients attending the center for health care between January and December 2008 were recruited into the study if they presented with the following characteristics: age 45 years or older; diagnosed with an illness that had produced chronic pain for at least 6 months before the start of the study; inclusion in the program to receive chronic medical prescriptions (with records of the daily dose, time interval, and duration of each treatment administered); and use of more than five boxes of analgesics during the study period. Patients were excluded if they had been referred to other primary care centers, had died, or moved out of the area.

Study groups in relation to use of analgesic medications
--------------------------------------------------------

Data about medicinal analgesic products were obtained from prescriptions of dispensed products collected from the pharmacies, according to the procedure for monitoring pharmaceutical prescriptions of CatSalut. Patients were selected if they regularly used nonopiate analgesics, nonsteroidal antiinflammatory drugs, or weak or strong opiates according to the Anatomical Therapeutic Chemical classification system.[@b21-ceor-4-039] Finally, two study groups were established according to the World Health Organization analgesic ladder, ie, patients in step 1--2 (taking nonopiates and weak opiates), and patients in step 3 (treated with strong opiates). Details of the active ingredients of the drugs taken are shown in [Table 1](#t1-ceor-4-039){ref-type="table"}.

Sociodemographic and comorbidity data
-------------------------------------

The main study variables were: age (continuous and by intervals) and gender, and the patient's personal background obtained from the CIAP-2[@b22-ceor-4-039] component 7 of illness and health problems: arterial hypertension (K86, K87), diabetes mellitus (T89, T90), dyslipidemia (T93), obesity (T82), smoking (P17), alcoholism (P15, P16), all types of organ failure (cardiac, hepatic and renal), ischemic heart disease (K74, K76, K75), stroke (K90, K91, K93), chronic obstructive pulmonary disease (R95, chronic airway obstruction), bronchial asthma (R96), dementia or memory disorders (P70, P20), neurological diseases \[Parkinson's disease (N87), epilepsy (N88), multiple sclerosis (N86) and other neurological diseases (N99)\]; and depressive syndrome (P76).

As a variable of general comorbidity for each patient attended in primary care, the Charlson Comorbidity Index[@b23-ceor-4-039] was used to give an approximation of the severity of the patient's condition, as well as the individual casuistic index, obtained from the adjusted clinical groups (ACG), and used to classify patients according to case-mix resource utilization. Mapping of the Clinical Information Access Portal was carried out according to international disease classification (ICD-9-CM). This was done by a working group comprising five experts (a documentalist, two clinicians, and two technical advisers). Different criteria were followed depending on whether no relationship (of one to none), a univocal relationship (of one to one), or a multiple relationship (from one to several) was established among the codes. The Grouper ACG^®^ case-mix system algorithm comprises a series of consecutive steps to obtain 106 mutually exclusive ACG groups, one for each patient.[@b24-ceor-4-039],[@b25-ceor-4-039] The ACG procedure provides resource utilization bands, such that each patient can be grouped in relation to their overall comorbidity into one of five mutually exclusive categories, ie, healthy users or ones with a very low morbidity, low morbidity, moderate morbidity, high morbidity, and very high morbidity.

Major morbidity categories
--------------------------

Following the recommendations of the Spanish Pain Association (Sociedad Española del Dolor), patients were classified into four specific groups or categories: malignant neoplasms (this includes any type of malignant or suspected neoplasm); neuropathic pain (direct lesion of the nervous system, including painful mononeuropathies \[posttraumatic, compressed nerve or radicular neuralgias\], painful polyneuropathies, neuropathic pain by deafferentiation \[eg, postherpetic neuralgia, amputation-induced neuromas, phantom limbs\], and complex regional pain syndrome); musculoskeletal alterations (produced by dysfunction or pathology of components of the musculoskeletal system, including arthropathies \[degenerative, inflammatory, crystalline deposits\], alteration of soft tissues, bone diseases, and connective tissue disorders); and other chronic alterations. One patient could be included in several of these categories at the same time.

Estimation of efficacy
----------------------

Given that there are no direct measures of efficacy, efficacy was estimated by considering five indicator measures, ie, treatment in a pain unit, specific analgesic treatment administered in a hospital, mean number of analgesics (nonopiate) per patient, and mean number of days of hospital stay per patient. Moreover, the patients treated in a hospital or pain unit were considered to be undertreated if they fulfilled either of the first two criteria but were not on stage 3 analgesics. In spite of the fact that this is a speculative definition, the authors consider that, in the absence of direct measures of efficacy, it can be considered to be accurate, particularly taking into account that a recent epidemiological study in Spain on the treatment of chronic noncancer pain reported that more than 60% of patients were on step 3 analgesia (personal communication). In the present study, we would expect this proportion to be even higher, considering that we also included cancer patients.

Use of resources and models of costs
------------------------------------

Direct health costs were considered to be those related to health care activity (eg, medical visits, days of hospital stay, emergencies, orders of diagnostic/therapeutic tests) and carried out by health care professionals. Non-health care-related or indirect costs were those related to lost work productivity (number of absentees and days of absenteeism). The design of the cost system was defined by taking into account the characteristics of the organizations and the degree of development of the information systems available. The product unit upon which the final calculation was based during the study period was the one the patient attended and the cost was expressed as mean cost per patient (cost/unit). The different study concepts and their economic analyses are shown in detail in [Table 2](#t2-ceor-4-039){ref-type="table"} (corresponding to data from 2008). The different fees were obtained from analytical accountancy data from each center, except for the cost of medication and days of absenteeism. Medical prescriptions (acute, chronic, or on demand) were quantified according to the recommended retail price per box at the time of prescription. Days of absenteeism or loss of productivity were considered as non-health care (indirect) costs. The cost was quantified in relation to the minimum interprofessional salary (sourced from Instituto Nacional de Estadística \[INE\]). In accordance with Spanish recommendations, the study protocol was approved by the Committee of Ethics of Clinical Research of the Foundation Gol and Gurina. All patients gave consent for their data to be used.

Confidentiality of data and statistical analysis
------------------------------------------------

As a previous step to the analysis, especially before studying the information source corresponding to patients' computerized clinical records, the data were carefully checked, observing their frequency distributions and possible errors in their recording or encoding. The confidentiality of data was respected according to the Organic Law on Data Protection (15/1999, of December 13). A descriptive univariate statistical analysis was conducted with mean values, standard errors/ deviations, and confidence intervals (CI) of 95%. The normality of the distribution was verified by the Kolmogorov-- Smirnov test. For bivariate analysis, Student's *t*-test, analysis of variance, and Chi-square and Pearson's linear correlation tests were used. The corrected comparison of undertreated patients with the rest of the patients treated in the pain unit or hospital was conducted according to the recommendations of Thompson and Barber,[@b26-ceor-4-039] by a multiple linear regression analysis (using a stepwise procedure, covariates of age and gender, and Charlson Comorbidity Index). A logistic regression was carried out to determine the association between comorbidities and use of strong opiates (enter procedure and Wald statistics). SPSSWIN software (v 17; SPSS Inc, Chicago, IL) was used to establish statistical significance at *P* \< 0.05.

Results
=======

From an initial selection of 45,929 individuals aged over 44 years assigned to and regularly attending six centers, a total of 18,157 patients were selected. The estimated prevalence of patients taking regular treatment for chronic pain was 39.5% (95% CI: 39.1--39.9). By study group, 17,747 (97.7%) patients were in step 1--2 of treatment and 410 (2.3%) in step 3 (*P* \< 0.001). The mean age of the patients was 66.2 years and 63.7% were women. The proportion taking opiate analgesia was 24.4% (n = 4427, 95% CI: 23.8--25.0).

[Table 3](#t3-ceor-4-039){ref-type="table"} shows the general characteristics of the series, the associated comorbidities, and measures associated with the efficacy in relation to treatment type. The subjects treated with step 3 analgesia were of a higher mean age (70.5 years versus 66.1 years; *P* \< 0.001), and a larger proportion of these were women (74.9% versus 63.4%; *P* \< 0.001). These subjects presented a greater overall comorbidity in episodes/patient (10.6 versus 7.6; *P* \< 0.001) and Charlson index (1.3 versus 0.7; *P* \< 0.001). In the corrected regression model, patients in step 3 presented a greater similarity in relation to cardiovascular events, odds ratio (OR): 1.9 (95% CI: 1.1--3.3), depressive syndrome, OR: 1.8 (95% CI: 1.5--2.3), female gender, OR: 1.7 (95% CI: 1.3--2.1), and arterial hypertension, OR: 1.3 (95% CI: 1.1--1.6, *P* \< 0.031). The intake of strong opiates was associated with cancer pain (OR: 1.6, 95% CI: 1.3--2.0). An estimated 2.3% of patients received step 3 analgesics, representing 4.7%, 3.3%, 2.2%, and 1.4% of patients with cancer pain, neuropathic pain, musculoskeletal pain, and pain of other origin, respectively.

The association between efficacy of treatment in the major diagnostic categories and study groups (analgesic treatment) is shown in [Table 4](#t4-ceor-4-039){ref-type="table"}. It is noteworthy that, using these indicators, on average 2.3% and 20.1% of patients did not receive adequate analgesia (undertreated) with step 1--2 analgesics when referred to the pain unit or admitted to hospital, respectively.

[Table 5](#t5-ceor-4-039){ref-type="table"} shows the cost model (average/unit) of the series studied in the different analgesic steps. Patients taking step 3 analgesics required more resources, as recorded on the prescriptions for analgesics and greater direct health care costs. However, the indirect costs were lower in these patients. The total cost of health care in these patients amounted to EUR 50.1 million, of which 89.9% corresponded to direct health care costs and 10.1% to indirect health care costs. The average/ unit of total costs (health-related, non-health-related) in subjects on step 3 of the analgesic ladder was €5764.1 versus €2686.9 (*P* \< 0.001).

Multiple linear regression models adjusted for patients treated in the pain unit and in the hospital are shown in [Table 6](#t6-ceor-4-039){ref-type="table"}. Undertreatment was associated with an increase in total costs compared with patients on step 3 treatment. However, owing to the minimal contribution of the variables included in the adjusted analyses to the total variables, the increase in costs could have other causes not recorded here, such as the more complicated clinical conditions.

Discussion
==========

In spite of the abundant information available on chronic pain, there are very few studies relating morbidity profiles to the treatments and resources utilized and the associated costs. This circumstance, together with the systematization of the database studied, makes this research of conceptual interest. The results suggest that step 3 analgesia is rarely used, and this is associated with an increase in direct costs. Nonetheless, without an appropriate standardization of the methodologies in relation to the patients' characteristics, and the number and measurement of the variables studied, the results obtained must be interpreted carefully and their external validity must be considered with caution.[@b27-ceor-4-039] An important contribution of this work was adjustment of morbidity on the basis of a case-mix resource utilization such as ACG.[@b24-ceor-4-039],[@b25-ceor-4-039]

The general results of our study show a prevalence of patients receiving regular treatment for chronic pain of around 39.5%, with a utilization of opiates in 24.4%. In spite of the variability among the studies reviewed, these percentages are slightly higher than those reported in studies of the general population.[@b6-ceor-4-039]--[@b9-ceor-4-039] This could be due to the fact that the patients studied in this work were aged over 44 years, and also due to the inclusion of patients with cancer pain. Nevertheless, the association of chronic pain with a larger proportion of osteoarticular problems (especially in the elderly, who have greater comorbidity), female gender, and mental illness, is similar to findings published previously.[@b5-ceor-4-039],[@b6-ceor-4-039] Regarding the analgesic regime in these patients, there appears to be an underutilization of step 3 analgesics, suggesting that many patients could be undertreated. There is also a clear underuse of opiates in most of the studies reviewed.[@b16-ceor-4-039],[@b17-ceor-4-039] Even doctors experienced at treating chronic pain show a reluctance to use opiates to treat severe noncancer pain. Our findings agree with those of Nicholson et al who suggest a need for doctors to receive better training in the use of opiates for analgesia.[@b29-ceor-4-039] Inadequate pain relief can have important depressive and emotional effects, causing suffering for patients and their relatives and also an increase in the use of health resources.[@b12-ceor-4-039],[@b20-ceor-4-039]

Since there is no direct measure of efficacy available, a patient was considered to be undertreated in a pain unit and/or when receiving analgesic treatment in a hospital if they did not receive any step 3 analgesics. This corresponded to 20.1% of patients in our study, and only 2.3% received strong opiates. It is difficult to draw comparisons with our results, although the use of strong opiates is similar to that described in the literature. A review by Galvez[@b30-ceor-4-039] describes how only 5% of patients in Europe received treatment with strong opiates, although there was some variability among countries. These percentages were higher (11%--13%) in Ireland, the UK, and Denmark, whereas this was only 1% in Spain. Nonetheless, we must take into consideration that the use of opiates to treat chronic noncancer pain has not been well established, because there are still only a few systematic reviews and meta-analyses for this type of long-term pain.[@b30-ceor-4-039]--[@b33-ceor-4-039] In clinical practice, treatment with opiates is conditioned by ethical, cultural, and legal considerations, because it can produce tolerance, adverse reactions, and physical dependence, leading to abstinence syndrome.[@b19-ceor-4-039] However, effective treatment of pain and the control of side effects is an attainable goal in most patients with chronic pain. Latest reports support effective analgesia, especially in severe pain, where opiates play a more prominent role, particularly with controlled-release formulations of morphine, oxycodone, and transdermal patches of fentanyl and buprenorphine, which have less pronounced side effects.[@b30-ceor-4-039] Patient response to these drugs may be variable, so treatment should be personalized. The mechanisms involved in irregular analgesic response and the appearance of side effects are not well known. Recently, a set of guidelines has been devised with the purpose of optimizing analgesic treatment with opiates. Briefly, these recommend adjusting the analgesic treatment to the intensity of pain, using the most appropriate route of administration for each patient, and monitoring the patient and dose with regular check-ups.[@b30-ceor-4-039],[@b34-ceor-4-039]

In the regression model, it is important to note that in routine clinical practice "undertreatment" was associated with costs even greater than in patients on step 3 of treatment. This could possibly be due to a selection bias, because the patients attended/selected who were being treated in the pain unit and/or hospital could, in general, present with more clinical complications than the others, and higher costs may be due largely to greater morbidity or severity. Nonetheless, since this comparison was made in the subgroup of patients treated in the pain unit or hospital, and, by definition, undertreated patients received step 3 analgesics (that have higher direct costs than the rest of the sample), this would suggest that the higher costs in the present study correspond to undertreated patients. A more appropriate, or better, treatment of these patients could reduce costs because an improvement in pain intensity, quality of life, or functionality would result directly in less use of health care resources.[@b12-ceor-4-039],[@b34-ceor-4-039],[@b35-ceor-4-039]

Possible limitations of this study lie in its limited geographical distribution, categorization of the disease (chronic pain), a possible bias in the classification of patients (analgesic step) and, especially, the lack of any direct measures of efficacy in the information system developed. Chronic pain conditions will most often possess many overlapping features between neuropathic, nociceptive, and even cancer pain syndromes. Categorizing chronic pain into distinct groupings may meet administrative requirements, but may not be functional in clinical practice. In addition, the World Health Organization ladder is based on subjective evaluation and a physician's clinical trial for the treatment of individual patients, so that could be considered by itself as a slightly objective parameter to assess the intensity of pain. In this study, we considered the World Health Organization analgesic ladder as a single indicator or isolated under treatment, as has always been taken into account in the quantitative administration of various drugs with the use of the expertise of pain. Therefore, this article reflects the limitations of the retrospective studies themselves; including an underrecording of the illness, its duration in time, or the possible doses of medication prescribed. Moreover, the variables that probably make an important contribution to establishing the costs present a clear dispersion among the regression models studied. In spite of these limitations, the results presented in this study still reflect a good approach to the pattern of use of analgesics in chronic pain. Future research must focus on cost/efficacy studies, for which direct measures of efficacy are required, and more controlled clinical trials to establish the role of opiate treatment in chronic pain of noncancer origin.

Conclusion
==========

The results of this study indicate that step 3 analgesics are underused, since up to a fifth of patients may be undertreated and present greater associated direct costs. However, regression analysis did not identify the proportion of excess cost that was attributable to undertreatment.

This study was financed by Grünenthal Pharma SA, which had no influence on the final results.

###### 

Distribution of different active ingredients included in the study according to therapeutic groups and classification of the World Health organization analgesic ladder

  WHO ladder     ATC       Active ingredient                  Boxes     \%       RRP            \%
  -------------- --------- ---------------------------------- --------- -------- -------------- --------
  Stage type 1   N02BE01   Paracetamol                        67,211    37.8%    204,215.94     14.1%
                 M01AE01   Ibuprofen                          26,612    15.0%    126,017.51     8.7%
                 N02BB02   Sodium metamizol                   9198      5.2%     22,764.70      1.6%
                 M01AB05   Diclofenac                         7715      4.3%     21,905.62      1.5%
                 M01AE17   Dexketoprofen                      7498      4.2%     50,342.20      3.5%
                 M01AB16   Aceclofenac                        5864      3.3%     46,906.17      3.2%
                 M01AE02   Naproxen                           3303      1.9%     21,230.60      1.5%
                 N03AX16   Pregabalin                         3274      1.8%     192,731.56     13.3%
                 N03AX12   Gabapentin                         2947      1.7%     121,063.44     8.3%
                 M01AB01   Indomethacin                       2660      1.5%     7347.14        0.5%
                 M01AC06   Meloxicam                          2494      1.4%     17,595.79      1.2%
                 M01AH01   Celecoxib                          1426      0.8%     52,961.64      3.6%
                           Other (NSAID analgesics)           8688      4.9%     125,412.62     8.6%
  Stage type 2   N02AX52   Tramadol (combinations)            9934      5.6%     61,292.78      4.2%
                 N02AX02   Tramadol                           8271      4.7%     151,615.23     10.4%
                 N02BE51   Paracetamol (combinations)         3957      2.2%     9600.97        0.7%
                 N02AA59   Codeine (combinations)             1690      1.0%     4849.84        0.3%
                 N02BA51   Acetyl salicylic acid (combined)   646       0.4%     1630.41        0.1%
  Stage type 3   N02AB03   Fentanyl                           2857      1.6%     160,003.15     11.0%
                 N02AE01   Buprenorphine                      816       0.5%     38,037.71      2.6%
                 N02AA01   Morphine                           586       0.3%     10,176.38      0.7%
                 N02AA05   Oxycodone                          194       0.1%     3524.15        0.2%
                 Total                                        177,841   100.0%   1,451,225.55   100.0%

**Abbreviations:** WHO, World Health Organization; ATC, Guidelines for ATC classification; NSAID, nonsteroidal anti-inflammatory drug; RRP, recommended retail price.

###### 

Unit costs of health care resources and productivity losses from absenteeism

  Health care resources and non-health resources   Unit costs (€)
  ------------------------------------------------ ----------------
  Medical visits                                   
   Visit to GP                                     22.74
   Visit to emergency service                      115.23
   Hospitalization (one day)                       314.61
   Specialist medical care (referral)              102.36
  Additional tests                                 
   Laboratory tests                                21.86
   Conventional x-ray                              18.14
   Diagnostic/therapeutic tests                    36.45
  Pharmaceutical prescription                      RRP
  Work productivity                                
   Cost per day of absenteeism                     54.65

**Note:** Source of health care data: authors' analytical accounts.

**Abbreviations:** GP, general practitioner; RRP, recommended retail price.

###### 

General characteristics of the series studied and measures related to efficacy in analgesic stages

  -------------------------------------------------------------------------------------------------------
  Study groups: analgesic step subjects, %   Type 1--2\       Type 3\       Total\            *P* value
                                             17,747 (97.7%)   410 (2.3%)    18,157 (100.0%)   
  ------------------------------------------ ---------------- ------------- ----------------- -----------
  Sociodemographic characteristics                                                            

  Mean age, years                            66.1 ± 11.3      70.5 ± 11.6   66.2 ± 11.3       \<0.001

   45--54 years                              17.7%            11.2%         17.5%             

   55--64 years                              29.5%            19.3%         29.3%             

   65--74 years                              26.8%            28.0%         26.8%             

   75--84 years                              20.7%            31.2%         21.0%             

   \>84 years                                5.3%             10.2%         5.4%              \<0.001

  Gender (women)                             63.4%            74.9%         63.7%             \<0.001

  **General comorbidity**                                                                     

  Mean RUB/patient                           3.0 ± 0.6        3.3 ± 0.6     3.0 ± 0.6         \<0.001

  1                                          2.2%             0.0%          2.2%              

  2                                          10.5%            4.1%          10.4%             

  3                                          75.0%            66.3%         74.8%             

  4                                          10.7%            23.9%         11.0%             

  5                                          1.5%             5.6%          1.6%              \<0.001

  Mean of episodes/patient                   7.6 ± 3.9        10.6 ± 5.2    7.7 ± 3.9         \<0.001

  Mean Charlson index                        0.7 ± 1.1        1.3 ± 1.4     0.7 ± 1.1         \<0.001

  **Associated comorbidities**                                                                

  Arterial hypertension                      50.6%            63.9%         50.9%             \<0.001

  Diabetes mellitus                          20.1%            31.0%         20.4%             \<0.001

  Dyslipemia                                 45.3%            44.5%         45.2%             NS

  Obesity                                    17.8%            18.7%         17.9%             NS

  Active smokers                             13.2%            10.3%         13.2%             NS

  Alcoholism                                 2.0%             1.5%          1.9%              NS

  Ischemic heart disease                     8.4%             14.0%         8.5%              \<0.001

  Stroke                                     9.6%             14.7%         9.7%              \<0.001

  Cardiovascular events                      16.4%            27.3%         16.7%             \<0.001

  Organic insufficiencies                    10.2%            17.2%         10.3%             \<0.001

  Bronchial asthma                           5.1%             7.1%          5.1%              0.039

  COPD                                       6.5%             8.4%          6.6%              NS

  Neuropathies                               1.1%             2.9%          1.1%              0.002

  Dementia (all types)                       2.0%             2.5%          2.0%              NS

  Depressive syndrome                        20.7%            34.4%         21.0%             \<0.001

  **Major diagnostic categories**                                                             

  Cancer pain                                9.0%             19.0%         9.2%              \<0.001

  Neuropathic pain                           29.7%            44.4%         30.0%             \<0.001

  Musculoskeletal pain                       81.2%            78.5%         81.2%             NS

  Other alterations                          11.3%            6.8%          11.2%             0.003

  **Measures related to efficacy**                                                            

  Patients visiting pain units               2.0%             18.3%         2.4%              \<0.001

  Hospital admissions                        17.8%            36.6%         18.2%             \<0.001

  Mean of active ingredients/patient         2.3 ± 1.3        4.5 ± 1.4     2.3 ± 1.4         \<0.001

  Mean of opiates/patient                    0.2 ± 0.4        1.5 ± 0.5     0.3 ± 0.5         \<0.001

  Mean of hospital stays/patient             1.2 ± 5.5        2.0 ± 8.5     1.4 ± 6.4         \<0.001
  -------------------------------------------------------------------------------------------------------

**Abbreviations:** RUB, resource utilization bands; COPD, chronic obstructive pulmonary disease; NS, not statistically significant.

###### 

Relationship between efficacy (pain unit, hospital treatment) and major diagnostic categories relative to the study groups (analgesic treatment)

  Characteristic pain unit    Present n = 439   Absent n = 17,772
  --------------------------- ----------------- -------------------
  **Step type 1--2 (n, %)**                     
  Cancer pain                 25 (1.6)          1577 (98.4)
  Neuropathic pain            220 (4.2)         5058 (95.8)
  Musculoskeletal pain        308 (2.2)         14,155 (97.9)
  Other alterations           23 (1.1)          1990 (98.9)
  Mean, %                     2.3               97.7
  **Step type 3 (n, %)**                        
  Cancer pain                 6 (7.6)           73 (92.4)
  Neuropathic pain            41 (22.4)         142 (77.6)
  Musculoskeletal pain        63 (19.3)         263 (80.7)
  Other alterations           7 (25.0)          21 (75.0)
  Mean, %                     18.6              81.4
  **Hospital treatment**      **n = 3322**      **n = 14,889**
  **Step type 1--2 (n, %)**                     
  Cancer pain                 460 (28.7)        1142 (71.3)
  Neuropathic pain            915 (17.3)        4363 (82.7)
  Musculoskeletal pain        2565 (17.7)       11,898 (82.3)
  Other alterations           332 (16.5)        1681 (83.5)
  Mean, %                     20.1              80.0
  **Step type 3 (n, %)**                        
  Cancer pain                 34 (43.0)         45 (57.0)
  Neuropathic pain            49 (26.8)         134 (73.2)
  Musculoskeletal pain        120 (36.8)        206 (63.2)
  Other alterations           11 (39.3)         17 (60.7)
  Mean, %                     36.5              63.5

###### 

Costs model (average/unit) of the series studied according to the different analgesic stages

  ----------------------------------------------------------------------------------------------------------------
  Study groups subjects, %                       Type 1--2\        Type 3\           Total\            *P* value
                                                 17,747 (97.7%)    410 (2.3%)        18,157 (100.0%)   
  ---------------------------------------------- ----------------- ----------------- ----------------- -----------
  **Cost in primary care**                       1942.5 ± 1294.9   3719.6 ± 2280.1   1982.7 ± 1351.2   \<0.001

  Visits to GP                                   273.7 ± 216.6     459.5 ± 301.8     277.9 ± 220.6     \<0.001

  Clinical tests                                 121.9 ± 97.2      137.8 ± 114.2     122.3 ± 97.6      \<0.001

  X-rays                                         88.3 ± 90.1       103.3 ± 103.5     88.7 ± 90.4       \<0.001

  Additional tests                               40.7 ± 63.3       60.9 ± 91.2       41.2 ± 64.2       \<0.001

  Referral to specialists                        627.3 ± 504.4     992.7 ± 896.7     635.6 ± 519.4     \<0.001

  Pharmaceutical prescription                    790.6 ± 866.4     1965.4 ± 1566.9   817.1 ± 905.2     \<0.001

  **Cost in specialist care**                    464.9 ± 1864.9    1786.0 ± 4255.3   494.7 ± 1961.0    \<0.001

  Hospital stay                                  405.0 ± 1834.8    1649.0 ± 4225.9   433.1 ± 1930.6    \<0.001

  Emergencies                                    59.8 ± 117.7      137.0 ± 202.6     61.6 ± 120.8      \<0.001

  **Total health care costs**                    2407.4 ± 2436.2   5505.6 ± 5046.4   2477.4 ± 2566.5   \<0.001

  Non-health care costs (days absenteeism)       279.5 ± 1423.6    258.5 ± 1578.4    279.0 ± 1427.2    NS

  Total cost (health care and non-health care)   2686.9 ± 2794.3   5764.1 ± 5265.2   2756.4 ± 2909.5   \<0.001
  ----------------------------------------------------------------------------------------------------------------

**Note:** Values expressed in Euros.

**Abbreviations:** GP, general practitioner; NS, not significant.

###### 

Multiple linear regression model with association between variable undertreatment and costs

  Variables of equation                                       Coefficient   95% CI
  ----------------------------------------------------------- ------------- ------------
  **Dependent: total costs (€) \[*R*^2^= 0.09\]**                           
  Constant[\*](#tfn7-ceor-4-039){ref-type="table-fn"}         3507          2626--4386
  Age, years                                                  10            −3--23
  Gender, man versus woman                                    −148          −440--143
  Charlson index[\*](#tfn7-ceor-4-039){ref-type="table-fn"}   975           868--1082
  Undertreatment (yes versus no)                              383           −69--836
  **Dependent: total costs (€) \[*R*^2^= 0.09\]**                           
  Constant[\*](#tfn7-ceor-4-039){ref-type="table-fn"}         4.07          3697--4442
  Age, years                                                  −50           −55--44
  Gender, man versus woman                                    −196          −319--73
  Charlson index[\*](#tfn7-ceor-4-039){ref-type="table-fn"}   −29           −74--16
  Undertreatment (yes versus no)                              −138          −329--54
  **Dependent: total costs (€) \[*R*^2^= 0.15\]**                           
  Constant[\*](#tfn7-ceor-4-039){ref-type="table-fn"}         −563          −1365--239
  Age, years                                                  60            48--71
  Gender, man versus woman                                    48            −218--314
  Charlson index[\*](#tfn7-ceor-4-039){ref-type="table-fn"}   1,004         906--1101
  Undertreatment (yes versus no)                              521           109--934

**Note:** Statistical significance (the confidence interval does not include 0).

**Abbreviations:** CI, confidence interval; *R*^2^, coefficient of determination of the model.
